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Heparin-associated antiplatelet antibodies (HAAb)
will develop in 2% to 5% of patients who undergo
heparin therapy.1-4 The formation of the HAAb is
independent of the type amount, or route of heparin
administered. The HAAb have been formed after low-
dose subcutaneous heparin therapy,5-7 after heparin
flushes,8 and even in patients in whom the only source
of heparin was heparin-coated pulmonary artery
catheters.9 The heparin-induced thrombocytopenia
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Purpose: This study was designed to determine the incidence rate of heparin-associated
antiplatelet antibodies (HAAb) in patients who require major vascular reconstruction
and to determine whether the HAAb were associated with perioperative thrombotic
events.
Methods: One hundred six patients who underwent elective arterial reconstruction for
cerebrovascular occlusive disease (n = 48), aortoiliac occlusive disease (n = 13), aortoil-
iac aneurysm (n = 17), mesenteric arterial occlusive disease (n = 1), or infrainguinal arte-
rial occlusive disease (n = 28) prospectively underwent evaluation from July 1, 1996, to
June 30, 1997. Heparin-associated antibody tests (with a two-point platelet aggregation
assay) and platelet counts (via Coulter counter) were performed before surgery and on
or after the 4th day after vascular reconstruction. Arterial reconstruction thromboses
were established by means of duplex ultrasound scanning or angiography. Acute myocar-
dial infarction (AMI) and venous thromboses were diagnosed with clinical criteria and
duplex ultrasound scanning, respectively. A significant decrease in platelet count was
defined as a platelet count of less than 100,000/mm3 or as a more than 30% drop in the
platelet count.
Results: Twenty-two patients (21%) had at least one positive HAAb assay: one assay was
positive before surgery only (after angiography), six were positive both before and after
surgery, and 15 were positive after surgery only. There were three perioperative deaths—
one in the HAAb-positive group and two in the HAAb-negative group. Ten thrombot-
ic events occurred in the perioperative period. Four thrombotic events (three operative
site thromboses and one AMI) occurred in the HAAb-positive group (18.2%). All of
these patients were undergoing heparin therapy. Of the six patients (with three opera-
tive site thromboses, two deep venous thromboses, and one AMI) in the HAAb-nega-
tive group (7%; P = .21), three were undergoing heparin therapy. No patient who was
HAAb positive with a thrombotic event had thrombocytopenia or a significant decrease
in platelet count.
Conclusion: The frequent exposure to heparin by patients with peripheral vascular dis-
ease is associated with a high incidence rate (21%) of HAAb formation, which makes it
one of the more common hypercoagulable conditions in these patients. The patients who
were HAAb positive had a 2.6-fold increase in perioperative thrombotic events.
Thrombocytopenia or decreasing platelet counts were not reliable clinical markers for
identifying patients who were HAAb positive. It is suggested that all patients who have
undergone heparin therapy and who have an unexplained perioperative thrombotic event
develop should undergo testing for HAAb. (J Vasc Surg 1999;29:779-86.)
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syndrome (HIT), with thrombotic or, rarely, hemor-
rhagic complications, will develop in some individuals
with HAAb when they are exposed to heparin. The
morbidity and mortality rates associated with HIT
have been as high as 61% and 23%, respectively.10
However, with early recognition and cessation of
exposure to heparin, the morbidity and mortality rates
have been reduced to 7.4% and 1.1%, respectively.11
Most patients for vascular surgery are exposed to
heparin during the diagnostic procedures or the vas-
cular reconstructions. This exposure to heparin may
lead to the development of HAAb, which may place
patients having vascular reconstructions at an
increased risk for graft thrombosis or other throm-
bosis-related complications. The purpose of this
study was to determine the incidence rate of HAAb
formation and HIT in patients for vascular surgery
who undergo reconstructive operative procedures
and to determine whether the HAAb or HIT were
related to postoperative thrombotic events.
METHODS
The study was approved by the Institutional
Review Board of the University of Missouri–Columbia.
One hundred six patients who underwent elective arte-
rial reconstruction between July 1, 1996, and June 30,
1997, underwent prospective evaluation. They under-
went 107 elective arterial reconstructions for cere-
brovascular occlusive disease (n = 48), aortoiliac occlu-
sive disease (n = 13), aortoiliac aneurysm (n = 17),
mesenteric arterial occlusive disease (n = 1), or infrain-
guinal arterial occlusive disease (n = 28). Tests for the
presence of HAAb and platelet counts were performed
before and on or after the 4th day after vascular recon-
struction. The timing for the postoperative HAAb test-
ing ranged from 4 days to 6 weeks after the procedure.
Fifty-nine of these patients also underwent testing
before diagnostic angiography.
Completion duplex scanning or arteriography
was performed for carotid endarterectomies and for
the visceral artery reconstruction. Intraoperative
arteriography was performed for the infrainguinal
bypass grafting procedures. Completion studies were
not performed in patients with aortoiliac aneurysmal
or occlusive disease.
Patients with acute thromboembolism and acute
ischemia (ie, those patients who required immedi-
ate heparin administration, emergent angiography,
or emergent surgery) were excluded from this
study. One patient who underwent a carotid
endarterectomy refused entry into this study.
Approximately 50 patients who qualified for entry
into this study were not tested for the presence of
HAAb in the preoperative period for logistical rea-
sons and therefore were not included.
Platelet counts were determined in the hemato-
logic laboratory with an automated blood cell counter
(Coulter Maxm, Coulter Corporation, Miami, Fla).
Thrombocytopenia was defined as a platelet count of
less than 100,000/mm3. A significant decrease in
platelet count was defined as a more than 30% drop in
consecutive samples. The diagnosis of HIT was made
according to the following criteria: (1) the develop-
ment of thrombocytopenia during heparin therapy,
(2) the resolution of thrombocytopenia after the ces-
sation of heparin therapy, (3) the exclusion of other
causes for thrombocytopenia, and (4) a positive
heparin-induced platelet aggregation assay.
Our method for the detection of the presence of
HAAb has been described previously.11 Briefly,
platelet-rich plasma (PRP) from healthy donors and
platelet-poor plasma from study patients were pre-
pared by means of differential centrifugation of whole
blood collected in a 3.8% citrate solution. The PRP
(0.1 mL) and the platelet-poor plasma (0.15 mL) were
combined and incubated for 3 minutes at 37°C. This
mixture was further incubated for an additional 15
minutes in a platelet aggregometer, with 25 m L of one
of the following three sources of heparin (final 
concentration, 1 anti-Xa U/mL): porcine intestinal
mucosa heparin (Solopak Laboratories, Elk Grove, Ill),
bovine lung heparin (Upjohn Company, Kalamazoo,
Mich), and enoxaparin (Lovenox, Rhone-Poulenc
Rorer Pharmaceuticals, Inc, Collegeville, Pa). Platelet
aggregation was measured with a dual channel aggre-
gometer (Chronolog Corporation, Havertown, Pa).
Aggregation was defined as a greater than 20% change
in optical density. If aggregation did not occur, 25 m L
of adenosine diphosphate (10–5 mol/L solution) was
added to ensure the proper reactivity of the donor
PRP.
The specificity of this test was increased with the
use of a two-point platelet aggregation assay. All the
patients whose test results were positive for the pres-
ence of HAAb underwent testing again with high-
concentration unfractionated heparin (final concen-
tration, 100 anti-Xa U/mL). If platelet aggregation
occurred with high-concentration heparin therapy,
the reactions were considered nonspecific.
In general, the protocol in our thromboembolic
laboratory is to repeat HAAb testing for 3 to 4 con-
secutive days in patients who have nonspecific reac-
tions. However, the samples for this study were
batch tested so that the results were often not avail-
able until days to weeks after the arterial reconstruc-
tion. Therefore, the tests with nonspecific platelet
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aggregation could not be repeated and were treated
as having negative results. Patients in whom the
diagnosis of HIT was suspected (because of decreas-
ing platelet count, thrombocytopenia, or unex-
plained thrombosis) immediately underwent testing
for the presence of HAAb.
Perioperative thrombotic complications (within
30 days after arterial reconstruction) were moni-
tored with clinical criteria, objective testing, or both.
Bypass graft patency was confirmed with postopera-
tive ankle-brachial indices and duplex ultrasound
scanning. Carotid endarterectomy patency was con-
firmed by means of duplex ultrasound scan studies.
The diagnosis of perioperative acute myocardial
infarction (AMI) was made on the basis of clinical
suspicion, appropriate electrocardiogram changes,
and elevated cardiac enzymes. The clinical diagnosis
of a lower extremity venous thrombosis was con-
firmed with duplex ultrasound scanning.
The percentages of perioperative thrombotic
complications in the HAAb-positive and HAAb-
negative groups were compared by means of the
Fisher exact test, with SAS statistical analysis soft-
ware (SAS Institute, Inc, Cary, NC). Significant dif-
ferences were those with a P value of less than .05.
RESULTS
Twenty-two patients (21%) had at least one pos-
itive assay for HAAb. One patient had a positive
assay before surgery only (after angiography). This
patient’s test results were positive for beef and pork
heparin but not for enoxaparin. The patient was
administered enoxaparin during and after surgery
and was undergoing enoxaparin therapy when tested
after surgery. Six patients had positive results both
before and after surgery. Four of these patients had
HAAb-positive tests before angiography or surgery,
and all had a history of heparin exposure. Only one
patient had a documented HAAb conversion after
exposure to heparin during angiography. The
remaining patient did not undergo HAAb testing
before the angiographic procedure. Fifteen patients
had positive results after surgery only.
The 107 operations were associated with three
perioperative deaths. One patient with HAAb died 6
weeks after the repair of a suprarenal aortic pseudo-
aneurysm. The patient was noted to have HAAb on
postoperative day 6. Multisystem organ failure, sep-
sis, and a secondary thrombocytopenia developed in
the patient. The other deaths occurred in two
patients without HAAb after femorotibial bypass
grafting. Both deaths were caused by fatal cardiac
events. One patient had an intraoperative myocardial
infarction while undergoing heparin therapy and
died 1 week later from cardiac arrest after urgent
coronary bypass grafting. The second patient had a
ventricular dysrhythmia in the recovery room and
recovered. However, 1 week after surgery, the
patient had cardiac arrest from which he could not
be resuscitated. Heparin therapy had been discon-
tinued in this patient 6 days before his death.
Ten thrombotic events occurred in the perioper-
ative period. Four thrombotic events occurred in the
22 patients who were HAAb positive, for an inci-
dence rate of 18.2%. There were three arterial recon-
struction thromboses and one AMI (Table I). Three
of the thrombotic complications occurred either in
the operating room or in the recovery room. All of
these patients had undergone unfractionated heparin
therapy for intraoperative anticoagulation. The
remaining patient had infrainguinal graft thrombosis
develop on postoperative day 6: he was undergoing
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Table I. Thromboses in patients who were positive for heparin-associated antiplatelet antibodies
Patient no. Type of surgery Thrombotic complication Clinical outcome Type of heparin therapy*
1 Infrainguinal bypass grafting Graft thrombosis, BKA Intraoperative,
POD 0 then continuous IV†
2 Carotid endarterectomy with Myocardial infarction, Patent bypass Intraoperative,
SCA-carotid bypass grafting POD 0 graft then continuous IV†
3 Carotid endarterectomy, Femoral artery AKA Intraoperative,
then aortic aneurysm repair thrombosis, during then continuous IV†
surgery
4 Infrainguinal bypass grafting Graft thrombosis, BKA Intraoperative,
POD 6 then subcutaneous bid‡
POD, Postoperative day; BKA, below-knee amputation; IV, intravenous; SCA, subclavian artery; AKA, above-knee amputation; bid,
twice a day.
*All patients were previously exposed to heparin.
†Patient underwent unfractionated heparin therapy after surgery for intraoperative or postoperative thrombotic complications.
‡Patient underwent low–molecular weight heparin and coumadin therapy after surgery for suboptimal venous conduit.
low–molecular weight heparin and coumadin thera-
py as a result of the presence of suboptimal venous
conduit. Three of the four patients ultimately under-
went lower extremity amputation (Table I).
Three arterial reconstruction thromboses, two
deep venous thromboses, and one AMI occurred in
the 84 patients who were HAAb negative, for an inci-
dence rate of 7% (Table II). Intraoperative throm-
botic complications (two native arterial thromboses
and one AMI) developed in three patients. All of
these patients had undergone unfractionated heparin
therapy for intraoperative anticoagulation before
their thromboses. Statistical analysis revealed a 2.6-
fold increase in thrombotic events in the HAAb-pos-
itive versus the HAAb-negative group (P = .21).
Two of the 22 patients who were HAAb positive
(9%) had significant decreases develop in their platelet
counts. Thrombocytopenia in association with sepsis
developed in one of the two patients, who ultimately
died of multisystem organ failure. The other patient
had a 50% decrease in platelet count after an
aorto–superior mesenteric artery bypass grafting pro-
cedure but had no perioperative thrombotic compli-
cations. Nine of the 84 patients who were HAAb neg-
ative (11%) had a significant decrease in platelet count
develop. There was only one thrombotic complica-
tion in the 11 patients with thrombocytopenia or a
decreasing platelet count (9%). A deep venous throm-
bosis was diagnosed in a patient who was HAAb neg-
ative 1 day after the patient developed thrombocy-
topenia (46,000/mL3). The platelet count returned
to normal (299,000/mL3) 3 days after heparin anti-
coagulation therapy was initiated.
By our definition, none of the 107 study patients
had HIT develop. Two of the patients who were
HAAb positive developed significant decreases in
platelet counts or thrombocytopenia. Sepsis was the
more likely cause for one patient. The other patient
had approximately a 50% decrease in the platelet
count without having any detectable thrombotic
complication.
DISCUSSION
Of the patients who undergo heparin therapy, 2%
to 9% (range, 0.9% to 31%)3,12 have HIT develop. The
incidence rate varies depending on the type of heparin
therapy, the route of administration, and the definition
of thrombocytopenia that is used. Most authors use a
platelet count of less than 100,000/mm3 to define
HIT-associated thrombocytopenia. Porcine heparin
appears to cause less HIT than does bovine heparin
(2.4% vs 9.1%).12 Low–molecular weight heparin caus-
es significantly less HIT than does unfractionated
heparin (0% vs 2.7%).4
The incidence rate of HAAb formation, regardless
of the presence or absence of thrombocytopenia,
varies widely depending on the indications for heparin
administration and the tests used to detect HAAb.
Patients who undergo subcutaneous unfractionated
and low–molecular weight heparin therapy for pro-
phylaxis against venous thromboembolism had
HAAb develop in 7.8% and 2.2% of the cases, respec-
tively.4 With an enzyme-linked immunosorbent assay
(ELISA), Jackson et al13 found a low incidence rate of
HAAb formation (3.7% before surgery and 5.5% after
surgery) in patients who underwent arterial recon-
struction, whereas Bauer et al14 detected HAAb in 5%
of the patients before cardiopulmonary bypass graft-
ing and in 13% by the 5th postoperative day with a
14C-serotonin-release assay (SRA). When an ELISA
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Table II. Thromboses in patients who were negative for heparin-associated antiplatelet antibodies
Patient no. Type of surgery Thrombotic complication Clinical outcome Type of heparin therapy*
1 Carotid endarterectomy Carotid occlusion, POD 1 No neurologic deficits Intraoperative
2 Aortic aneurysm repair Tibial artery thrombosis, TMA Intraoperative
during surgery
3 Aortofemoral bypass grafting Femoral artery thrombosis, Successful thrombectomy Intraoperative,
during surgery then continuous IV†
4 Infrainguinal bypass grafting Myocardial infarction, Fatal cardiac arrest Intraoperative,
during surgery then continuous IV†
5 Aortic aneurysm repair DVT Uneventful Intraoperative,
then continuous IV‡
6 Infrainguinal bypass grafting DVT PE/IVC filter Intraoperative,
then continuous IV‡
POD, Postoperative day; TMA, transmetatarsal amputation; IV, intravenous; DVT, deep venous thrombosis; PE, pulmonary embolus;
IVC, inferior vena cava.
*All patients were previously exposed to heparin.
†Patient underwent unfractionated heparin therapy after surgery for intraoperative thrombotic complications.
‡Patient underwent unfractionated heparin therapy after surgery after the diagnosis of deep venous thrombosis was established.
was used in the same group of patients, HAAb were
detected in 19% and 51% during the preoperative
and postoperative periods, respectively.14 The
results of this current study are similar to those
obtained with the 14C-SRA used in Bauer’s study.
With a two-point platelet aggregation assay, we
detected HAAb before surgery in 7% and after
surgery in 20% of the patients who underwent arte-
rial reconstruction. The other discrepancies may be
explained, in part, by the tests that were used to
detect the presence of HAAb.
The most widely used assays for the detection of
HAAb are the SRA and the two-point platelet aggre-
gation assay. These functional assays depend on the
binding of HAAb to the platelet membrane FcRII
receptor, which is specific for immunoglobulin G
class immunoglobulins. The SRA has a sensitivity of
approximately 94% and a specificity that ranges from
90% to 100%.15 With platelets from donors with a
known reactivity to HAAb, the two-point platelet
aggregation assay has a similar sensitivity (88%) and
specificity (82% to 100%).16,17 Although the ELISA
(an antigen assay) is being used more frequently for
the detection of HAAb, several authors describe a
10% to 48% discordance in results when compared
with functional assays.18-20 Immunoglobulin M or
immunoglobulin A class antiheparin antibodies may
be detected with ELISA, but their clinical relevance
remains unknown. On the other hand, the presence
of immunoglobulin G that recognizes nonheparin
antigens may result in a positive functional assay and
a negative ELISA.21 Some authors use the function-
al assays and ELISA to complement each other, per-
forming both tests when one provides a negative
result.21
Although 21% of the 106 patients had at least
one positive HAAb assay, the true number of
patients with HAAb may be higher than recorded.
For this study, blood was obtained for HAAb testing
and platelet counts before and at least 4 days after
any elective vascular reconstruction. Some patients,
whose test results were negative on the 4th postop-
erative day, if they underwent testing again later,
may have had a positive result. Similarly, some
patients who underwent testing up to 6 weeks after
their procedure may have had a low titer of HAAb
that was not detectable.
A significant number of patients were undergo-
ing heparin therapy (prophylactic or therapeutic) at
the time of HAAb testing. We use subcutaneous
unfractionated or low–molecular weight heparin
therapy liberally for prophylaxis against venous
thrombosis. Therapeutic heparin anticoagulation
therapy is reserved for patients with acute throm-
botic processes (myocardial infarction, deep venous
thrombosis, or native arterial or graft thrombosis) or
for patients who require long-term anticoagulation
therapy with oral warfarin (atrial fibrillation, pros-
thetic lower extremity bypass grafting, etc). Some
patients who are HAAb positive may have had false-
ly negative test results as a result of the consumption
of HAAb in the formation of immune complexes.
This is a phenomenon that is well described (hidden
rheumatoid factor) in the immunology and rheuma-
tology literature.22,23 Because of the nature of this
study, the blood samples were batch tested for
HAAb and the results were not always immediately
available for the clinician. Routinely, if there is high
clinical suspicion for HIT and negative test results
for HAAb, we recommend that heparin therapy be
discontinued and that the test be repeated daily for
up to 4 days. We have never seen a patient have pos-
itive results after negative test results on 4 consecu-
tive days.
Patients with established HIT frequently have
venous or arterial thrombotic complications develop
(up to 53% to 61%).10,24 Our group has demon-
strated that the HIT-related morbidity and mortali-
ty rates may be reduced to 7.4% and 1.1%, respec-
tively, with the early recognition of the presence of
HAAb and the prompt cessation of heparin admin-
istration.11 The association between the presence of
HAAb (without a clinical diagnosis of HIT) and
perioperative thrombotic complications has been
recognized. Hach-Wunderle et al25 identified five
patients in whom HAAb-related graft thromboses
developed, despite the presence of normal platelet
counts. The patients all had positive test results for
HAAb with platelet aggregation and serotonin
release tests.
Our current study confirms that HAAb-related
thrombotic complications may occur despite the
absence of thrombocytopenia. Four of 22 patients
who were HAAb positive (18.2%) had perioperative
thrombotic complications develop. None of these
patients had thrombocytopenia develop or showed a
significant decrease in their platelet counts. Of the
11 patients who had either thrombocytopenia or a
significant decrease in their platelet count develop,
two were HAAb positive (9%). One of the two
patients had thrombocytopenia associated with sep-
sis and multisystem organ failure develop. The other
patient had a 50% decrease in the platelet count after
an aorto–superior mesenteric artery bypass grafting
procedure. Neither of these patients had a thrombo-
hemorrhagic event.
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During the perioperative period, thrombocytope-
nia may not be a reliable index for the presence of
HAAb. HIT may be a late clinical finding that occurs
after the prolonged administration of heparin. If we
had used the clinical criteria of a falling platelet
count, thrombocytopenia, or a thrombotic event as
an indication to test for the presence of HAAb, we
would have found an incidence rate of approximate-
ly 5%. Despite this finding, the monitoring of platelet
counts during heparin therapy still is a valuable tool,
especially at institutions where HAAb testing may
not be readily available.
The true incidence rate of thrombotic complica-
tions may have been underestimated by this study. All
the patients who underwent endarterectomy or
bypass grafting procedures underwent evaluation
with noninvasive vascular tests. However, the patients
did not undergo screening for asymptomatic myocar-
dial infarctions or for silent venous thromboses. Most
likely, the number of these patients is quite small and
would not have affected our results.
Although this review was not designed to address
the management of HIT, the data clearly indicate
that the early recognition of the presence of HAAb
and the cessation of the administration of the sensi-
tizing heparin are most important.11 All the patients
who undergo testing for HAAb should also undergo
testing for crossreactivity to low–molecular weight
heparins and heparinoids (enoxaparin, dalteparin,
and danaparoid). The crossreactivity ranges from
10% to more than 60%, with danaparoid having the
lowest rate (10% to 20%).26,27 We have had success
with various low–molecular weight heparin prepara-
tions when crossreactivity testing results were nega-
tive.28 However, the recent availability of danaparoid
and r-hirudin (a direct thrombin inhibitor) will make
these antithrombotic agents more widely applicable
to most patients who are HAAb positive.
CONCLUSION
The development rate of HAAb is quite high
(21%) in patients for vascular surgery who undergo
diagnostic and reconstructive procedures. Although
not statistically significant (P = .21), the presence of
these antibodies was associated with a 2.6-fold
increased risk for perioperative thrombotic events.
These antibodies may be the most commonly acquired
hypercoagulable disorder experienced by patients who
undergo diagnostic and subsequent vascular recon-
struction procedures. Vascular surgeons should have a
high index of suspicion whenever an unexplained peri-
operative thrombocytopenia or thrombosis occurs and
should test for the presence of HAAb.
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Dr John Hoch (Madison, Wis). That was a well present-
ed study. I have just an observation. This month, in the
Journal of Vascular Surgery, Jackson et al (1998;28:439-45)
from Walter Reed in a smaller series prospectively studied
patients undergoing a similar distribution of arterial recon-
structions. They used an enzyme-linked immunosorbent
assay (ELISA) against heparin and platelet factor 4 and
found an incidence rate of only 2% of their patients tested
positive for heparin-associated antibodies. The study to
which you alluded by Bauer et al (Circulation 1997;
95:1242-6), looked at patients for cardiac surgery. The inci-
dence rate in that study was up to 50% of patients. So, we see
a wide variability in the incidence rate of heparin antibody
undergoing different forms of arterial reconstruction.
I have just a couple of questions for you. There has
been some evidence that prior heparin exposure may influ-
ence thrombotic complications afterward. In your group
of patients, did you document prior exposure or not? And
did it affect the incidence rate of heparin antibody after
the procedure?
Another observation in the literature is that the length
of heparin exposure after surgery may have an influence on
heparin antibody presence. In fact, the four patients in
your series who did have heparin-associated antibodies
and thrombotic events all were maintained on continuous
heparin after surgery. I wonder what your observations are
about that?
And then last, the old paradigm that many of us have
used to monitor platelet counts after vascular surgery pro-
cedures while maintaining patients on heparin seems to be
going by the wayside on the basis of your experience in
this prospective study, mainly that none of your patients
who had thrombotic complications had thrombocytope-
nia. What are your thoughts about that? Do we still need
to follow patients with daily platelet counts on heparin
exposure after surgery? And last, what are your insights
and what are you folks doing in Missouri now relative to
the commercially available ELISA kits that are present?
Should we be screening all our patients who we know have
had heparin exposure before surgery? What are your
thoughts about that?
Thank you.
Dr John G. Calaitges. Thank you for those com-
ments. The first question alludes to the recent paper in the
Journal of Vascular Surgery. I think the main difference
between the two studies is the assay that was used to iden-
tify the heparin antibodies. Our assays are two-point
platelet aggregation assays that have been shown by
Warkeutin’s group (Throm Haemost 1998;79:1-7) to be
at least 95% sensitive in identifying the presence of heparin
antibodies. He has also shown that the platelet factor 4
assay has a 10% to 20% discordance with both false posi-
tives and false negatives with regard to identifying the
presence of heparin antibodies.
We have looked into developing an ELISA that would
identify heparin antibodies and thus obviate the need for
donor platelets. Over the past 5 or 6 years, we have inves-
tigated this intensely and have not been able to correlate
the results with the ELISA assay with what we were
obtaining in the lab with known positives and negatives.
Therefore, we have not felt comfortable at this time rec-
ommending the ELISA for clinical identification of these
heparin antibodies.
The next question talked about the influence of previ-
ous exposure, and I think that is a strong indicator for the
potential presence of heparin antibodies and a more rapid
development of these antibodies. Three of our four
thrombotic complications occurred either during surgery
or immediately after surgery, and I am sure that these
patients were presensitized because of their diagnostic or
previous surgical exposure to heparin.
As far as monitoring platelet counts, we recommend
that you still monitor platelet counts. I think that throm-
bocytopenia is an indicator of heparin antibody presence,
although it may be a late indicator. And certainly in many
areas where people do not have immediate access or the
ability to run heparin assays, following the platelet count
is probably the most sensitive indicator that they have. I
think that, coupled with a high index of suspicion and
early cessation of heparin for any unexplained postopera-
tive or perioperative thrombotic complication, is probably
the best recommendation at this point.
We do not currently recommend routine screening for
these patients. I do not think that the ELISA kit at this
DISCUSSION
time is sensitive enough to provide adequate routine
screening. Also, the mere presence of heparin antibodies
does not always lead to adverse clinical effects, and, there-
fore, knowing up front may not alter your management.
Keeping a high index of suspicion is probably the main
recommendation from this paper.
Dr Darwin Eton (Los Angeles, Calif). Is there an
increased incidence rate of heparin-induced thrombocy-
topenia syndrome in dialysis patients because they are
repetitively exposed to heparin?
Dr Calaitges. We did not look at that specifically, but
there was one patient who before surgery and before
angiography had a heparin assay that was positive and that
patient was on dialysis. We have not looked at that specific
population to look for the presence of heparin antibodies.
Dr Alexander Shepard (Detroit, Mich). What are your
current recommendations or guidelines for checking platelet
counts in patients on heparin? Obviously, checking them
every day would be the ideal situation, but this would be a
fairly expensive proposition if you included every patient
who was on subcutaneous, low-dose heparin therapy or who
had a heparin-bonded catheter in place. Can you give us any
suggestions or guidelines for how frequently we should be
monitoring platelets in patients in these situations?
Dr Calaitges. We monitor patients who are on intra-
venous heparin daily for platelet counts. We do not use
heparin-bonded catheters in our institution, and we have
gotten away from subcutaneous unfractionated heparin.
Our main population that we are monitoring is patients
who are on a continuous intravenous drip, and, in those
patients, we follow the platelet counts very closely.
Dr Gregorio Sicard (St Louis, Mo). I would like to
ask you a question. What do you do with the patients who
do have these antibodies but do not have an adverse
effect? As you know, much of our practice involves reop-
erative surgery, so when they come back what do you do
with them? If they have had the antibody, do you retest
them? And if they have it, do you alter your antithrom-
botic therapy?
Dr Calaitges. Yes, we do. Anybody who has a known
past positive heparin antibody assay is retested before
surgery. If that test is still positive, we test against beef and
pork heparin, the low–molecular weight heparins, and hep-
ranoids. It is rare that somebody is positive to all five of
those products, but in the event that they are, we would
recommend the recombinant hirudin preparation. We have
not had to use that in the intraoperative setting yet, but we
have recently had an experience in the postoperative setting
in which somebody had positive results to all of those
heparin preparations and was kept on combinant hirudin.
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CORRECTION
The editors regret noting that they omitted mentioning that the paper “The US Food and Drug
Administration investigational device exemptions (IDE) and clinical investigation of cardiovascular devices:
Information for the investigator” by William F. Pritchard et al was a joint publication with Journal of Vascular
and Interventional Radiology. The paper, which appeared in the Journal of Vascular Surgery in March 1999,
was published in JVIR 1998;10:115-22.
